Turnover crosses Rs 4500 crore in 2010-11
Ahmedabad based pharma major Zydus Cadila has ended the financial year 2010-11 with revenues touching $1 billion(over Rs 4500 crore) mark.
Chairman and managing director of Zydus Cadila, Pankaj Patel said,"When we began our journey to the billion in 2006-07, we knew it would be a big leap forward. This has been the result of an all-round effort in terms of strengthening existing businesses, building new capabilities and venturing into new geographies. Our expansive vision continues as we move beyond the billion." The company had touched the $400 million mark in 2007. Zydus' key markets including US, France, Spain, Japan, Brazil and South Africa have contributed to this goal by growing at more than 40 per cent.
With over 300 new product launches that include over 60 first-in-India launches, the India formulations business has been the mainstay of the operations. The group is also present in the women’s healthcare, gastrointestinals, respiratory and cardiovascular segments. It has also forayed into specialised areas like dermatology, nutraceuticals, hepatology and rheumatology and has set up new specialty divisions. It also launched the country's first indigenous swine flu vaccine VaxiFlu-S in 2010.
Moreover, the group's consumer business was restructured and integrated into Carnation Nutra Analogue Foods Ltd. Renamed as Zydus Wellness Ltd, the company now spearheads the Zydus group’s presence in the fast growing consumer healthcare market. Zydus at present also has 12 investigational new drug (IND) under various stages of clinical trials.The group begins its march beyond the billion with a thrust on new portfolios such as vaccines, biologics and transdermals. The group has set up Zydus Vaccine Technology Centre, Zydus Biologics and Zydus Technologies to spearhead its foray in these segments. Besides,it has also set up joint ventures with Abbott, Bayer, Hospira and Nycomed.
Starting out after a vertical split in the erstwhile Cadila Laboratories in 1995 the group has posted an 18 fold growth over the last 15 years. With a modest beginning as an India focussed company and a turnover of Rs 200 crores, the group is today the fifth largest Indian pharmaceutical company in the country at present.
